What does adding glucagon-receptor activation contribute beyond dual agonism
In a recent trial studying the effectiveness of tirzepatide (Zepbound) for weight loss, participants lost an average of 20.9% of their body weight at 36 weeks
Use of twice-daily exenatide in Basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial
The results of HE staining showed that compared with the control group, the model group had swollen hepatocytes and vacuolar changes (mainly steatosis)
The demographics tell an important story too
How It Works in Research It activates GIP, GLP-1, and glucagon receptors in your body - making you feel fuller longer, helping your body use insulin more effectively, and increasing your metabolic rate to burn more calories throughout the day